GlassScriptPhysician profile
Emmanuel C Okafor
NPI 1477655959
$3,773.37
in general payments reported to CMS, 2019-2025
20 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $129 · 2021: $157 · 2022: $921 · 2023: $1,025 · 2024: $791 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.90 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,104.50 | 2019-2025 | |
| Janssen Biotech, INC. | $244.83 | 2019-2024 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $222.31 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $184.03 | 2021-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $183.86 | 2022 | |
| Gilead Sciences, INC. | $164.31 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.03 | 2019-2023 | Xifaxan, Plenvu |
| Viiv Healthcare Company | $124.99 | 2024 | |
| Ardelyx, INC. | $107.32 | 2022-2023 | Ibsrela |
| Celgene Corporation | $56.90 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $53.17 | 2022-2023 | |
| Pfizer INC. | $48.20 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.61 | 2023 | Dupixent |
| Braintree Laboratories, INC. | $24.06 | 2022 | |
| Amgen INC. | $20.91 | 2023 | Amjevita |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.07 | 2024 | |
| Shire North American Group INC | $16.54 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.92 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.06 | 2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.75 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Okafor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.